Granata Bio’s mission and focus is to create access for fertility patients by introducing new therapeutic solutions
our purpose
While incidence of infertility in the US mirrors that of other developed countries, the cost of US fertility treatment is often borne by the patient, and this presents a significant barrier to treatment. The price of IVF medications has increased by 50% since 2014 (GoodRx), meanwhile only 14 states have passed fertility insurance coverage laws that include IVF coverage (Resolve: The National Infertility Association). As a result, the rate of utilization of ART services, in most of the US, is amongst the lowest in the world.
Founded in 2018, Granata Bio's model is to identify and in-license strategic medications used in IVF outside of the US for clinical development and commercialization in North America. By doing so, we hope to expand therapeutic options for patients, decrease cost, and increase access to care for every patient seeking fertility treatment on their path to parenthood.
Cost is the biggest barrier to fertility treatment
Assisted reproductive technology (ART) affordability and utilization
Utilization
ART Affordability (%)
ART Affordability is expressed as the net cost of a fresh IVF cycle as a percentage of annual disposable income of a single person earning 100% of average wages with no dependent children. Disposable income is calculated according to Organization for Economic Co-operation and Development (OECD) methods.
Utilization is expressed as the number of fresh autologous cycles per one million women of reproductive age (15–49 years).
Chart is adapted from Chambers. Global ART cost and consequences. Fertil Steril 2013.
Granata Bio has over 75 years’ experience in women’s health and reproductive health
Experienced in clinical development, regulatory and commercialization
Experienced in regulatory requirements for reproductive health products
Strong network of stakeholders in the field of fertility
About the US Reproductive Health Market
i.
A relatively young medical field, the US reproductive health market is rapidly evolving landscape from a scientific, technological and business standpoint.
ii.
Recent advances in treatment have helped improve success rates, reduce rates of multiple
gestations and decrease time to pregnancy.
iii.
While disease awareness and utilization
of Assisted Reproductive Technology (ART)
services has increased, drug development
in infertility has stagnated.
iv.
Granata Bio understands that competition spurs innovation. New market entries, aimed at increasing competition and improving the patient experience, will benefit both clinical and patients in this rapidly growing market.
Granata Bio Founding Team
Evan Sussman
-
Evan is the Chief Executive Officer and a Co-Founder of Granata Bio, a US based biopharma company focused on women’s health and fertility. In his role, Evan is responsible for Granata Bio’s corporate, customer, and commercial strategies.
Before founding Granata Bio, Evan spent nine years at EMD Serono/Merck KgAA. Most recently, he served as the Marketing and Business Unit Head for the US Fertility/Fertility Technologies businesses. During this time, Evan spearheaded the creation of innovative programs aimed at expanding access to care for under-recognized patient groups. He has previously served on the corporate council of RESOLVE: The National Infertility Association and the American Society of Reproductive Medicine.
Evan is a graduate of Brown University and received an MBA in Healthcare Leadership from Yale University. He lives in the Boston area with his wife and two children. Outside of work, you can find Evan trail running, golfing, or hiking with his family.
Sarah Faranda
-
Sarah’s experience spans 14 years and includes work at multiple Pharmaceutical Advertising Agencies. Sarah has worked in both the Global and US markets and has played a pivotal role across product lifecycles—working on product launches to rebranding efforts for established brands.
Sarah is passionate about her experience in fertility and women’s health, and it has been the focus of her career over the past 10 years. Sarah has experience working on campaigns with Teva Women’s Health, Ferring Fertility and EMD Serono Fertility.
Sarah lives in the Northern New Jersey with her husband and two kids.
David Paller
-
David focuses on business development, accounting operations, fundraising and strategy activities for Granata Bio. David financial executive experiences are wide ranging within the healthcare sector ranging from biotech to medical device and healthcare delivery companies. A biomedical engineer by training, David assists with the development of hundreds of medical devices in various capacities ranging from start-ups to the leading global medical device manufacturers. As a member of the research faculty of the Alpert Medical School of Brown University, David authored over 40 original manuscripts while also providing business and strategy mentorship to various biotech and medical device organizations.
Dave received an MBA in Healthcare Leadership from Yale University. He lives in Rhode Island with his wife and three kids.
Marc Chung
-
With over 15 years of life science consulting experience, Marc has led strategy development, clinical operations process optimization, FDA submission projects for large pharmaceutical and biotechnology companies. Marc’s experience at Quintiles (IQVIA) uniquely qualifies him to lead Granata Bio’s clinical development and regulatory activities.
Marc has a BA from The Johns Hopkins University and an MPH & MBA from Yale University. He lives in Connecticut with his wife and two children.
About the US Reproductive Health Market
i.
A relatively young medical field, the US reproductive health market is rapidly evolving landscape from a scientific, technological and business standpoint.
ii.
Recent advances in treatment have helped improve success rates, reduce rates of multiple
gestations and decrease time to pregnancy.
iii.
While disease awareness and utilization
of Assisted Reproductive Technology (ART)
services has increased, drug development
in infertility has stagnated.
iv.
Granata Bio understands that competition spurs innovation. New market entries, aimed at increasing competition and improving the patient experience, will benefit both clinical and patients in this rapidly growing market.
Granata Bio Founding Team
Evan Sussman
Sarah Faranda
-
Evan is the Chief Executive Officer and a Co-Founder of Granata Bio, a US based biopharma company focused on women’s health and fertility. In his role, Evan is responsible for Granata Bio’s corporate, customer, and commercial strategies.
Before founding Granata Bio, Evan spent nine years at EMD Serono/Merck KgAA. Most recently, he served as the Marketing and Business Unit Head for the US Fertility/Fertility Technologies businesses. During this time, Evan spearheaded the creation of innovative programs aimed at expanding access to care for under-recognized patient groups. He has previously served on the corporate council of RESOLVE: The National Infertility Association and the American Society of Reproductive Medicine.
Evan is a graduate of Brown University and received an MBA in Healthcare Leadership from Yale University. He lives in the Boston area with his wife and two children. Outside of work, you can find Evan trail running, golfing, or hiking with his family.
-
Sarah’s experience spans 14 years and includes work at multiple Pharmaceutical Advertising Agencies. Sarah has worked in both the Global and US markets and has played a pivotal role across product lifecycles—working on product launches to rebranding efforts for established brands.
Sarah is passionate about her experience in fertility and women’s health, and it has been the focus of her career over the past 10 years. Sarah has experience working on campaigns with Teva Women’s Health, Ferring Fertility and EMD Serono Fertility.
Sarah lives in the Northern New Jersey with her husband and two kids.
David Paller
-
David focuses on business development, accounting operations, fundraising and strategy activities for Granata Bio. David financial executive experiences are wide ranging within the healthcare sector ranging from biotech to medical device and healthcare delivery companies. A biomedical engineer by training, David assists with the development of hundreds of medical devices in various capacities ranging from start-ups to the leading global medical device manufacturers. As a member of the research faculty of the Alpert Medical School of Brown University, David authored over 40 original manuscripts while also providing business and strategy mentorship to various biotech and medical device organizations.
Dave received an MBA in Healthcare Leadership from Yale University. He lives in Rhode Island with his wife and three kids.
Marc Chung
-
With over 15 years of life science consulting experience, Marc has led strategy development, clinical operations process optimization, FDA submission projects for large pharmaceutical and biotechnology companies. Marc’s experience at Quintiles (IQVIA) uniquely qualifies him to lead Granata Bio’s clinical development and regulatory activities.
Marc has a BA from The Johns Hopkins University and an MPH & MBA from Yale University. He lives in Connecticut with his wife and two children.